Table 2. Cell cycle distribution analysis in i.p. tumour xenografts of LS-174T after treatment with paclitaxel and 212Pb-TCMC-trastuzumab RIT.
| |
|
Time point (h) |
|||||
|---|---|---|---|---|---|---|---|
| Treatment | Phase | 0 | 6 | 24 | 48 | 72 | 96 |
| |
G1 |
67.5±2.7 |
|
|
|
|
|
| |
S |
17.7±2.0 |
|
|
|
|
|
| |
G2-M |
14.8±0.7 |
|
|
|
|
|
| Paclitaxel-212Pb-Trastuzumab | G1 | 58.9±2.9 | 67.9±0.2 | 68.2±1.4 | 63.9±0.1 | 75.8±2.7 | |
| S | 17.5±3.7 | 7.6±0.4 | 6.9±0.1 | 6.3±0.0 | 5.5±0.3 | ||
| |
G2-M |
|
23.6±0.8 |
24.5±0.6 |
24.9±1.2 |
29.8±0.0 |
18.8±3.0 |
| Paclitaxel-212Pb-HuIgG | G1 | 69.3±5.9 | 56.5±0.4 | 68.5±0.1 | 66.3±0.0 | 64.2±1.7 | |
| S | 14.7±0.1 | 17.8±0.7 | 5.0±0.2 | 5.9±0.1 | 16.1±4.0 | ||
| |
G2-M |
|
16.0±5.8 |
25.7±0.4 |
26.5±0.1 |
27.8±0.1 |
19.7±2.2 |
| Paclitaxel | G1 | 63.3±1.5 | 63.6±0.2 | 68.1±0.2 | 68.0±1.6 | 73.3±0.2 | |
| S | 22.1±3.0 | 18.9±1.0 | 14.3±0.0 | 12.4±0.5 | 11.7±0.5 | ||
| |
G2-M |
|
14.6±1.5 |
17.5±0.8 |
17.6±0.2 |
19.6±1.1 |
15.1±0.4 |
| 212Pb-Trastuzumab | G1 | 68.6±3.8 | 66.9±1.3 | 67.7±4.0 | 68.1±1.3 | 66.6±0.7 | |
| S | 14.3±5.4 | 5.9±0.1 | 6.3±1.8 | 7.9±0.7 | 3.6±0.0 | ||
| |
G2-M |
|
17.1±1.6 |
27.3±1.2 |
26.1±2.1 |
23.9±0.6 |
29.7±0.7 |
| 212Pb-HuIgG | G1 | 63.9±5.2 | 65.1±2.3 | 64.6± | 67.1±0.5 | 63.1±0.3 | |
| S | 20.0±5.3 | 7.4±1.3 | 5.8± | 5.5±0.1 | 7.8±0.7 | ||
| G2-M | 16.0±0.1 | 27.5±1.0 | 29.6± | 27.4±0.6 | 29.1±1.0 | ||
Abbreviation: RIT=radioimmunotherapy.
Mice bearing i.p. LS-174T xenografts were pretreated with paclitaxel before 212Pb-TCMC-trastuzumab RIT. Additional groups included untreated, paclitaxel alone, 212Pb-TCMC-trastuzumab without paclitaxel pretreatment and 212Pb-TCMC-HuIgG with/without paclitaxel pre-treatment. Results represent the average of a minimum of three replications (±s.d.).